SCHEMBL16369966

SCHEMBL16369966

CC1(COC(=O)c2ccccc2)CCCC(F)(F)CO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.39
▸ ADRB2 P07550 1/20 0.39
▸ ADRB1 P08588 1/20 0.39
▸ ADRB3 P13945 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.38
▸ PRKCA P17252 4/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 2/20 0.37
▸ HIF1A Q16665 1/20 0.37
▸ SLC6A2 P23975 1/20 0.37
▸ SLC6A3 Q01959 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CHRNB2 P17787 1/20 0.36
▸ CHRNA5 P30532 1/20 0.36
▸ CHRNA7 P36544 1/20 0.36
▸ CHRNA4 P43681 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ ICMT O60725 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16369964 1.00 LMNA (0.39) LMNAADRB2ADRB1ADRB3TDP1
SCHEMBL15105686 0.86 LMNA (0.42) LMNAADRB2ADRB1ADRB3TDP1
SCHEMBL15105687 0.86 LMNA (0.42) LMNAADRB2ADRB1ADRB3TDP1
SCHEMBL16369971 0.86 LMNA (0.42) LMNAADRB2ADRB1ADRB3TDP1
SCHEMBL18573967 0.83 LMNA (0.44) LMNAADRB2ADRB1ADRB3TDP1
SCHEMBL15106123 0.79 ICMT (0.43) LMNAADRB2ADRB1ADRB3TDP1
SCHEMBL15106124 0.79 ICMT (0.43) LMNAADRB2ADRB1ADRB3TDP1
SCHEMBL16369934 0.78 LMNA (0.39) LMNATDP1PRKCATSHRMAPK1
SCHEMBL16369933 0.78 LMNA (0.39) LMNATDP1PRKCATSHRMAPK1
SCHEMBL16370113 0.77 CHRNB2 (0.41) LMNATDP1TSHRMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3019196-B1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-06-06 — — EP disclosed
EP-3019196-B1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-06-06 — — EP disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 — — US disclosed
US-20160158200-A1 Combinations of Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2016-06-09 — — US disclosed
EP-3019196-A1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2016-05-18 — — EP disclosed
US-20150297568-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2015-10-22 — — US disclosed
US-20150023913-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2015-01-22 — — US disclosed
WO-2015005901-A1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-15 — — WO disclosed
WO-2015005901-A1 COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150023913-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, EIF2AK2 LMNA 4392/4885ADRB2 4798/4885ADRB1 4542/4885
US-20150297568-A1 Hepatitis C Virus Inhibitors HAVCR2, MAVS, EIF2AK2 LMNA 4392/4885ADRB2 4798/4885ADRB1 4542/4885
US-20160158200-A1 Combinations of Hepatitis C Virus Inhibitors HAVCR2, EIF2AK2, MAVS LMNA 4275/4885ADRB2 4783/4885ADRB1 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback